Skip to main content

CDSCO

 

Clinical courses

  • Opportunity for M.Pharm or B.Pharm as Bench Chemist at CDSCO

    The Central Drugs Standard Control Organization (CDSCO) is the Central Drug Authority for discharging functions assigned to the Central Government under the Drugs and Cosmetics Act. CDSCO has six zonal offices, four sub-zonal offices, 13 port offices and seven laboratories under its control.

    Post : Bench Chemist

  • Recruitment in Pharmacovigilance TDA (10 posts) at CDSCO - M.Pharm Apply | Pay Rs. 52,500 pm

    The Central Drugs Standard Control Organisation under Directorate General of Health Services, Ministry of Health & Family Welfare,Government of India is the National Regulatory Authority (NRA) of India. Its headquarter is located at FDA Bhawan, Kotla Road, New Delhi 110002 and also has six zonal offices,four sub zonal offices,thirteen Port offices and seven laboratories spread across the country.

  • Opportunity for B.Pharm as Bench Chemist (04 posts) at CDSCO

    The Central Drugs Standard Control Organisation (CDSCO) under Directorate General of Health Services,Ministry of Health & Family Welfare,Government of India is the National Regulatory Authority (NRA) of India. Its headquarter is located at FDA Bhawan, Kotla Road, New Delhi 110002 and also has six zonal offices,four sub zonal offices,thirteen Port offices and seven laboratories spread across the country.

  • Job opportunity for Director post of CDSCO, Ministry of Health and Family Welfare

    On August 7, 2014 vide extraordinary Gazette notification Part –II Section-3, Sub Section(ii) New Delhi Thursday August 7, 2014, Department of AIDS Control has been merged with Department of Health & Family Welfare and now be known as National AIDS Control Organization (NACO).

  • Bharat Biotech Intranasal vaccine receives CDSCO nod for booster

    Bharat Biotech International Limited a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced that iNCOVACC® (BBV154), has received approval from the Central Drugs Standard Control Organisation (CDSCO) under Rcstrictcd Use in Emcrgcncy Situation for ages 18 and above, in India, for heterologous booster doses.

  • Applications are invited for a post of Director in CDSCO

    The Central Drugs Standard Control Organisation (CDSCO) under Directorate General of Health Services,Ministry of Health & Family Welfare,Government of India is the National Regulatory Authority (NRA) of India. Its headquarter is located at FDA Bhawan, Kotla Road, New Delhi 110002 and also has six zonal offices,four sub zonal offices,thirteen Port offices and seven laboratories spread across the country.

    Post : Director (Vigilance)

  • Jobs for MPharm or MSc at Regional Drugs Testing Laboratory, CDSCO

    The Regional Drugs Testing Laboratory Guwahati is the one of the five National Laboratory of the Govt of India for quality control of Drugs and Cosmetic and is established under the Indian Drugs & Cosmetics Act 1940 functioning under administrative control of the Drugs Controller General of India and sub ordinate office under Directorate General of Health Services, Ministry of Health & Family Welfare. The laboratory was set up in the year 2002 for entire North Eastern State including Sikkim and is housed in its own building at Guwahati.

  • Shilpa medicare bags CDSCO approval for Tranexamic Acid Spray

    Shilpa medicare gets CDSCO approval for Tranexamic Acid Spray, Hemostatic Spray. The product is protected by granted patents in India till 2037 and in US, Australia, Russia and South Africa till 2038. Shilpa is continuously pursuing patent prosecution in other countries and for further protection.

  • BE receives CDSCO Panel nod to manufacture pneumococcal conjugate Vaccine

    Biological E. Limited (BE)'s 14-valent paediatric vaccine (investigational pneumococcal polysaccharide conjugate vaccine PCV14) is approved by the Subject Expert Committee of CDSCO  against S. pneumoniae infection in infants.

    Streptococcus pneumoniae infection continues to be a leading cause of child mortality under 5 years of age in India and in developing countries. With the PCV14 vaccine, Biological E hopes to contribute to the prevention of invasive pneumococcal disease and protect millions of lives globally.

  • Abbott got CDSCO panel nod to market Lidocaine and Diltiazem combination

    Abbott received permission from the Subject Expert Committee to market a fixed dose combination (FDC) of Lidocaine and Diltiazem, after detailed deliberation by committee.

    Abbott has presented a Phase III clinical trial report before the committee and after detailed deliberation, the committee recommended grant of permission for manufacturing and marketing of the proposed FDC.

Subscribe to CDSCO